|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
As demonstrated by Northern blot analysis, AIDS-KS cells as well as tumor cells show a high expression level of the VEGF gene as compared to primary human vascular cells like smooth muscle cells or endothelial cells.
|
1567395 |
1992 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors.
|
1550962 |
1992 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In situ analysis of tumour specimens undergoing neovascularization show that the production of VEGF is specifically induced in a subset of glioblastoma cells distinguished by their immediate proximity to necrotic foci (presumably hypoxic regions) and the clustering of capillaries alongside VEGF-producing cells.
|
1279431 |
1992 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These observations strongly support the concept that tumour angiogenesis is regulated by paracrine mechanisms and identify VEGF as a potential tumour angiogenesis factor in vivo.
|
1279432 |
1992 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Our findings indicate that VEGF/VPF is a tumor angiogenic factor.
|
7688963 |
1993 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The relative abundance of the forms of VEGPF mRNA was consistent in tumor and normal brain: VEGPF495 > VEGPF363 > VEGPF567.
|
8380810 |
1993 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Crucial in tumor angiogenesis are the paracrine actions of tumor-secreted factors (e.g., vascular endothelial growth factor), which have been thought to derive from the tumor epithelial cells themselves.
|
7525053 |
1994 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These results suggest that VEGF is produced by the tumor cells and is responsible for development of this hypervascular tumor.
|
7846687 |
1994 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These data support previous reports, which stated that VEGF/VPF acts as a paracrine growth and permeability factor in brain tumors and may contribute to tumor growth by initiating tumor angiogenesis.
|
7528359 |
1994 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These findings suggest that VEGF is produced and secreted by glioma cells and acts on tumor endothelial cells which express VEGF receptors.
|
7525492 |
1994 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Recent studies demonstrated a key role for VEGF in tumor neovascularization, which is a prerequisite for tumor proliferation and metastasis.
|
8589021 |
1995 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In this study we have examined the possibility that VEGF may also play an autocrine role in tumour growth.
|
8554590 |
1995 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Stabilized VEGF transcripts in tumor cells are refractile or nearly refractile toward further stabilization by TPA or hypoxia, respectively.
|
8930020 |
1995 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
By immunohistochemistry, VEGF protein was detectable in the tumor interstitium and was found to be concentrated around capillaries.
|
7533661 |
1995 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Abundant message for VEGF was found in all tumors, localized to the malignant cells within each neoplasm.
|
7535799 |
1995 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
VEGF is known to be produced by several tumor cells and plays an important role for neovascularization in tumor tissue.
|
8558848 |
1995 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The cells were further modified with a chronic benzo(a)pyrene exposure and were termed HOK-16B-BaP-T cells (1) demonstrated a malignant phenotype in organotypic 'raft' culture, (2) showed in vitro anchorage-independency, (3) developed tumors in nude mice when injected subcutaneously, (4) contained a significantly higher copy number of intact and integrated HPV-16 DNA; (5) contained higher level of HPV-16 E6/E7 messages and E7 protein, (6) were more resistant to transforming growth factor-beta 1 and (7) secreted higher level of vascular endothelial growth factor with molecular weight of 56 kd than parental HOK-16B-BaP cells.
|
7784058 |
1995 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Substantial expression of the receptors for VEGF is restricted mainly to the tumour blood vessels.
|
8527839 |
1995 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We aimed to clarify the function of VEGF in tumor development by identifying the cells in ovarian carcinoma tissue that express VEGF and its receptors.
|
7707437 |
1995 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The expression of vascular endothelial growth factor depends on activated oncogenes and inactivated tumor-suppressor genes as well as several other factors, e.g., growth factors, hypoxia, and tumor promoters.
|
8806195 |
1996 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Neovascularization stimulated by VEGF occurs in several important clinical contexts, including myocardial ischemia, retinal disease, and tumor growth.
|
8756616 |
1996 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Transfection did not influence the in vitro growth rate of the cell lines, but the tumors from the VPF-transfected lines had higher growth rates in vivo than tumors from the parental line or the vector-transfected line.
|
8644861 |
1996 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
PD-ECGF expression in human colon cancer specimens is associated with vessel count and may be responsible for tumor vascularity in those tumors with low VEGF expression.
|
8757194 |
1996 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
To determine whether the expression of vascular endothelial growth factor (VEGF) is altered by treatment in an in vivo tumor with 17 beta-estradiol (E2) or medroxyprogesterone acetate (MPA).
|
8626126 |
1996 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Our results suggest that angiogenesis observed in our assay may be due to the synergic effects of tumor angiogenic factors such as VEGF, and Matrigel.
|
8690516 |
1996 |